Skip to main content

Growth in Research

Read about the Department of Medicine's remarkable growth in research in FY26. 

Dr. Jim Oates in white coat

Message from the Vice Chair for Research

Research in the Department of Medicine begins with a clinical problem that has no good answer yet.

This year, these problems included a heart muscle stiffened by misfolded protein, a liver quietly scarring in a patient who came in for something else, and a lupus flare that has not responded to any of our medications. Our investigators pursue these questions because they encounter them in clinic, and because the distance from the laboratory bench to the patient’s bedside is short here, often a single corridor.

Fiscal Year 2026 was a demanding year for biomedical research nationally. Federal competition intensified, and review cycles grew less predictable. Despite this, our enterprise held and then grew. Total research funding reached a departmental record, and our faculty sustained a portfolio spanning basic mechanisms, first-in-human trials, and the health of communities across South Carolina. Specifics of these accomplishments appear on the following page. What they represent is harder to tabulate: grant applications written after clinic, protocols revised for the eleventh time, and patients who consented to a trial without knowing whether it would help them.

Three commitments shape how we intend to build from here. We will protect time for early-career investigators, because a K award defended today is an R01 a decade from now. We will keep our trials open to the patients most often excluded from them, including those with comorbid disease and those who live far from Charleston. And we will keep asking questions that cross division lines, because the biology rarely respects them. The work described in these pages belongs to our faculty, our trainees, and the people who trusted us with their care.

Jim Oates, M.D.
Vice Chair for Research
Department of Medicine

FY26 Research Funding and Activity

FY26 research funding reached $53,477,259, an increase of 4.6% from FY25 and 27.7% from FY22. The portfolio combined federal awards with substantial corporate, foundation, institutional, state and other support.

Department of Medicine FY26 Research Funding & Activity at a glance including: $53.48M in research funding, 97 new awards, 208 total awards, 500+ publications, and 433 active clinical trials

Department of Medicine 2026 Annual Report: 5-Year Research funding trend graph showing that FY26 research funding reached $53,477,259, an increase of 4.6% from FY25 and 27.7% from FY22.

FUNDING SOURCES and SUPPORT Table showing:Corporate: $25.8 MillionFederal: $18.5 MillionCollege or University: $4.3 MillionFoundations: $3.5 MillionState of South Carolina and other support: $1.4 Million

Major Funding Milestones and Grant Portfolios

The FY26 portfolio included investigator-initiated R-series awards, large center and cooperative agreement mechanisms, training grants, career development awards and Veterans Affairs support. New NIH R01 awards to Andrew Schreiner, M.D., MSCR, and Betty Tsao, Ph.D., expanded the department’s work in metabolic liver disease detection and the genetic basis of systemic lupus erythematosus. A new NHLBI K23 award to Michele Esposito, M.D., strengthened the cardiovascular clinician-scientist pipeline.

Center and Training Infrastructure

Active mechanisms included the SCTR UM1, the Telehealth Center of Excellence U66, P30 centers in digestive diseases and rheumatic diseases, and a portfolio of T32, TL1, R25 and UE5 programs. These awards provide shared research capacity, multicenter coordination and structured training across career stages.

FY26 Funding Highlights

Melissa Cunningham, M.D., Ph.D., Rheumatology & Immunology

  • R01 - The Role of Estrogen Receptor Alpha Variant Size and Localization in Modulating TLR7-Induced Inflammation, NIH/NIAMS

Kristine DeLeon-Pennell, Ph.D., Cardiology

  • R01 - Temporal Effects of CD8 T-cells Post-MI, NIH/NHLBI

Federica del Monte, M.D., Ph.D., Cardiology

  • R01 - Red Blood Cells Shuttle Beta Amyloid Between Brain and HEART: IMPLICATIONS for the Pathogenesis and the Progression of Alzheimer's and Cardiomyopathy, NIH/NHLBI

Susan Dorman, M.D., Infectious Diseases

  • R01 - Tuberculosis Trials Consortium, CDC
  • R34 - Novel strategies for treatment of Mycobacterium abscessus pulmonary disease

Carol Feghali-Bostwick, Ph.D., Rheumatology & Immunology

  • R25 - ASCEnD - A National Program of Academic Support and Coaching for Entrepreneurial Development, NIH/NIGMS
  • R33 - Peptides for the Treatment of Pulmonary Fibrosis, NIH/NHLBI
  • T32 - Pulmonary-Focused Foundations in Innovation and Scholarship (PUFFINS), NIH/NHLBI
  • TL1 – NRSA Training Core, NCATS

Patrick Flume, M.D., Pulmonary & Critical Care

  • UM1 - The South Carolina Clinical & Translational Research Institute (SCTR), NIH/NCATS

Dee Ford, M.D., Pulmonary & Critical Care

  • U66 - Telehealth Center of Excellence, HRSA

Gary Gilkeson, M.D., Rheumatology & Immunology

  • U01 - A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of Refractory Lupus (MiSLE), NIH/NIAID
  • T32 - Training Grant in Inflammatory and Fibrosing Diseases, NIH/NIAMS

Brian Hess, M.D., Hematology & Oncology

  • R01 - Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL, NIH/NCI

Russell Jenkins, M.D., Ph.D., Hematology & Oncology

  • R37 - Dissecting the Tumor-intrinsic and -extrinsic Roles of TBK1 in Tumor Immunity, NIH/NCI

Donald Menick, Ph.D., Cardiology

  • R01 - Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Post Myocardial Infarction, NIH/NHLBI

Jim Oates, M.D., Rheumatology & Immunology

  • P30 - Improving Health in Rheumatic Diseases (ImHeaRD), NIH/NIAMS

Kurt Prins, M.D., Ph.D., Cardiology

  • R01 - GP130 Antagonism in Porcine RV Pressure Overload, NIH/NHLBI
  • R01 - Multi-scale Investigation of Sex Differences in Right Ventricular Function via Estrogen-Microtubule Interactions, NIH/NHLBI

Don Rockey, M.D., Gastroenterology & Hepatology

  • R01 - A Molecular Approach to the Pathogenesis of Portal Hypertension, NIH/NIDDK
  • UE5 - Medical University of South Carolina Mentoring Program in Digestive and Liver Diseases, NIH/NIDDK
  • P30 - MUSC Digestive Disease Research Core Center, NIH/NIDDK
  • R25 - MUSC GI and Hepatology Medical Student Training Program, NIH/NIDDK

Andrew Schreiner, M.D., General Internal Medicine

  • R01 - Advanced Fibrosis Detection and a Predictive Diagnostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care, NIH/NIDDK (new in FY26)

Garth Swanson, M.D., Gastroenterology & Hepatology

  • R01 - The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis, NIH/NIDDK

Ryan Tedford, M.D., Cardiology

  • R01 - Phenotyping Net Immune State with MicroRNAs in Cardiac Transplantation, Inova Center for Personalized Health (sub award)

Betty Tsao, Ph.D.

  • R01 - Identify Rare Pathogenic Variants and their Functional Consequences in SLE, NIH/NIAMS (new in FY26)

Jeffrey Winterfield, M.D., Cardiology

  • R44 - Eliminating Ventricular Tachycardia: First in Human Clinical Trial using the Durablate™ Catheter, Thermedical Inc. (sub award)

John Wrangle, M.D., Hematology & Oncology

  • HT9425 - Leveraging Lineage Addiction: Nuclear Delivery of Therapeutic Transgenes Responsive to Oncogenic, Transcription Factor Over-Expression, DOD/USAMRAA
  • R21 - Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ, NIH/NCI

Yosra Alkabab, M.D., Infectious Diseases

  • K23 - Metabolic Syndrome Outcomes Among Patients with Tuberculosis in Tanzania, NIH/NIAID

DeAnna Baker Frost, M.D., Ph.D., Rheumatology & Immunology

  • K08 - The Role of Hormonal Dysregulation in Systemic Sclerosis, NIH/NIAMS

Michele Esposito, M.D., Cardiology

  • K23 - Regional Disparity of Skeletal Muscle Microvascular Dysfunction in Systolic Heart Failure, NIH/NHLBI (new in FY26)

Carol Feghali-Bostwick, Ph.D., Rheumatology & Immunology

  • K24 - Scleroderma Twin Study and Analysis of Estrogen in Patients with dcSSc, NIH/NIAMS

Ludivine Renaud, Ph.D., Rheumatology & Immunology

  • K01 - Epigenetic Regulation of KLF4 in SSc-Associated Lung Fibrosis, NIH/NIAMS

Charles Terry, M.D., Pulmonary & Critical Care

  • K12 – “Prospective Identification and Characterization of ARDS Using Computational Phenotypes.”

Jessica English. M.D., Rheumatology & Immunology

  • K12 – “Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus.”

Michele Esposito, M.D., Cardiology

  • K12 – “Mechanisms of Skeletal Muscle Microvascular Dysfunction in Systolic Heart Failure.” (new in FY26)

FY26 Research in the News

FY26 research advanced new therapeutic platforms, earlier detection strategies and evidence based improvements in care delivery. The following studies illustrate how department investigators connected laboratory science, clinical trials, data science and implementation research to address complex disease.